Estabrook Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Estabrook Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,000	Closed	-$5.49K	–	420
2022 Q4	$5.49K	Hold	7,000	–	–	﹤0.01%	335
2022 Q3	$5K	Hold	7,000	–	–	﹤0.01%	334
2022 Q2	$4.41K	Sell	7,000 -3,000	-30%	-$1.89K	﹤0.01%	363
2022 Q1	$6.97K	Hold	10,000	–	–	﹤0.01%	341
2021 Q4	$7K	Buy	+10,000	New	+$7K	﹤0.01%	353

Other funds holding NWBO

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

GWI

Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Estabrook Capital Management's NWBO Position: Q1 2023 in Review

Estabrook Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2023, closing a stake of 7,000 shares — an estimated $5.49K sold.

Estabrook Capital Management first reported a position in NWBO in Q4 2021 and held it in 5 quarters. The position peaked at $7K in Q4 2021. 14 funds tracked by Wall St. Rank hold NWBO as of Q1 2023.

Estabrook Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2023 after selling out during the quarter.
Estabrook Capital Management sold 7,000 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2023, an estimated $5.49K.
Estabrook Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2021 and held it in 5 quarters.
Estabrook Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $7K in Q4 2021.
14 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2023.

Based on Estabrook Capital Management's 13F filing for Q1 2023, filed 12 May 2023.